NCT00843934Unknown2 期
Randomized Controlled Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 450
- 试验地点
- 1
- 主要终点
- response rate
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be histologically or clinically proven HCC, inoperable, no indication of local treatment and has measurable lesions.
- •Subject must to be the first experience of TACE.
- •Subject has no extra-hepatic tumor and no obstruction of main portal vein.
- •Subjects must have fully recovered from previous treatment (at least 4 weeks interval is needed from prior chmotherapy or radiation therapy).
- •ECOG performance status 0-2
- •Child-pugh Class A or B
- •Subject must have adequate functions of bonemarrow, renal, circulatory organs and appropriate examination results as below:
- •Serum Total Bilirubin 2.0mg/mL
- •WBC 3000/mm3
- •PLT 50000/mm3
- •Creatinine ; upper normal limit (UNL)
- •BUN 25mg/dL
- •Written informed consent
排除标准
- •Subject has extra hepatic metastasis.
- •Tumor thrombosis exists at main portal vein.
- •Remarkable artery-portal vein shunt or veno-arterial shunt.
- •Uncontrollable ascites or pleural effusion.
- •History of severe hypersensitivity.
- •Any previous TACE or TAE for HCC.
- •Any previous chemotherapy using epirubicin or CDDP.
- •Complications as below (except chronic hepatitis or liver cirrhosis)
- •Severe heart disease
- •Myocardial infarction within 6 months
- •Renal insufficiency
- •Active infections (except virous hepatitis)
- •Gastrointestinal bleeding
- •Active double cancer
- •Hepatic encephalopathy or heavy mental disorder.
- •Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant.
- •Any subject judged by the investigator to be unfit for any reason to participate in the study.
研究组 & 干预措施
anti-cancer agent
Experimental
干预措施: epirubicin (Drug)
anti-cancer agent
Experimental
干预措施: Cisplatin (Drug)
结局指标
主要结局
response rate
时间窗: 6 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT04523467Eastern Hepatobiliary Surgery Hospital320
已完成
1 期
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor MalignanciesSolid TumorNCT00215501Dana-Farber Cancer Institute54
招募中
不适用
DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled TrialHCCNCT05788835Xuhua Duan220
已完成
不适用
A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancerBiliary TractBiliaryCancerISRCTN73941125The Royal Marsden NHS Foundation Trust (UK)
撤回
不适用
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein InvasionHepatocellular CarcinomaNCT01857726Seoul National University Hospital